Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burger

Showing results (681-690 of 1,123) with videos related to

Pageof 113
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 1, 1990
rab3 is a small GTP-binding protein exclusively localized to synaptic vesiclesG Fischer von Mollard, G A Mignery, M Baumert, et al.
Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment|September 14, 2010
Simple intervention method to reduce fumonisin exposure in a subsistence maize-farming community in South AfricaL van der Westhuizen, G S Shephard, J P Rheeder, et al.
British Journal of Cancer|November 4, 2010
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancerI M E Desar, J N H Timmer-Bonte, D M Burger, et al.
International Journal of Antimicrobial Agents|February 11, 2017
Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation?E J Smolders, S Pape, C T M M de Kanter, et al.
The Journal of Arthroplasty|August 1, 2024
Regional Periprosthetic Joint Infection Centers: The Time Has Come for a Paradigm Change in the Treatment of Periprosthetic Joint InfectionAlexander R Dombrowsky, Josef E Jolissaint, Samuel L Posey, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2006
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicityMark A Boyd, Umaporn Siangphoe, Kiat Ruxrungtham, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 27, 2011
Fumonisin B1 as a urinary biomarker of exposure in a maize intervention study among South African subsistence farmersLiana van der Westhuizen, Gordon S Shephard, Hester M Burger, et al.
British Journal of Clinical Pharmacology|September 8, 2017
Drug-drug interaction potential in men treated with enzalutamide: Mind the gapGuillemette Emma Benoist, Inge M van Oort, Stella Smeenk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulatorGurmeet Kaur, Dorina Belotti, Angelika M Burger, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapyJintanat Ananworanich, Meena Gorowara, Anchalee Avihingsanon, et al.
Pageof 113

Showing results (681-690 of 1,123) with videos related to

Sort By:
Pageof 113
Proceedings of the National Academy of Sciences of the United States of America|March 1, 1990
rab3 is a small GTP-binding protein exclusively localized to synaptic vesiclesG Fischer von Mollard, G A Mignery, M Baumert, et al.
Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment|September 14, 2010
Simple intervention method to reduce fumonisin exposure in a subsistence maize-farming community in South AfricaL van der Westhuizen, G S Shephard, J P Rheeder, et al.
British Journal of Cancer|November 4, 2010
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancerI M E Desar, J N H Timmer-Bonte, D M Burger, et al.
International Journal of Antimicrobial Agents|February 11, 2017
Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation?E J Smolders, S Pape, C T M M de Kanter, et al.
The Journal of Arthroplasty|August 1, 2024
Regional Periprosthetic Joint Infection Centers: The Time Has Come for a Paradigm Change in the Treatment of Periprosthetic Joint InfectionAlexander R Dombrowsky, Josef E Jolissaint, Samuel L Posey, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2006
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicityMark A Boyd, Umaporn Siangphoe, Kiat Ruxrungtham, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 27, 2011
Fumonisin B1 as a urinary biomarker of exposure in a maize intervention study among South African subsistence farmersLiana van der Westhuizen, Gordon S Shephard, Hester M Burger, et al.
British Journal of Clinical Pharmacology|September 8, 2017
Drug-drug interaction potential in men treated with enzalutamide: Mind the gapGuillemette Emma Benoist, Inge M van Oort, Stella Smeenk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulatorGurmeet Kaur, Dorina Belotti, Angelika M Burger, et al.
Antimicrobial Agents and Chemotherapy|January 19, 2012
Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapyJintanat Ananworanich, Meena Gorowara, Anchalee Avihingsanon, et al.
Pageof 113